Stryker Corp lifted its full-year profit forecast on Tuesday, owing to resilient demand for the company's medical devices and implants. The joint-implant maker now sees its annual profit per share to be between $11.85 and $12.05, raised from the previous range of between $11.70 and $12. Stryker now expects organic net sales growth for 2024 to be in the range of 8.5% to 9.5%, compared with its earlier projected range of 7.5% to 9%.
The headline numbers for Stryker (SYK) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Strong Organic Sales Growth and Improved Operating Margins Highlight the Quarter